MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMARepresents the second EMA approval of an MVA-BN-based vaccine for a younger ...
(RTTNews) - Bavarian Nordic A/S (BAVA) Thursday said that the European Commission has adopted the Committee for Medicinal Products for Human Use (CHMP) recommendation for the approval of a type II ...
In a recent study, one dose of modified vaccinia Ankara-Bavarian Nordic vaccine had estimated vaccine effectiveness of 58%. HealthDay News — One dose of modified vaccinia Ankara-Bavarian Nordic ...